Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Inclusion Criteria: * Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT * Fasting triglyceride levels \>140 and \< 400 mg/dl and values varying less than 35% between two screening measurements * Normal liver function tests and white blood cell count Exclusion Criteria: * Type 2 Diabetes for \> 3 years or HbA1c ≥ 7.5 * Known or suspected Type 1 Diabetes * Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin * Creatinine \> 2.0 mg/dl or other evidence of active kidney disease * Hepatic enzyme elevation \> 2x normal * Known Nonalcoholic Fatty Liver Disease * Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems * Recent history of nausea or vomiting * Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks * A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months * Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (\>1 g/day) * Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation.